Welcome to our dedicated page for PARKERVISION SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PARKERVISION's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PARKERVISION's regulatory disclosures and financial reporting.
ParkerVision, Inc. files a prospectus supplement updating its April 19, 2019 prospectus to register the resale of 12,800,000 shares of Common Stock, consisting of up to 7,800,000 shares issuable upon conversion of convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant. The company will not receive proceeds from resale by selling stockholders; to the extent the warrant is exercised for cash, the company would receive up to $800,000, which it expects to use for patent enforcement actions and general corporate purposes.
The supplement incorporates ParkerVision's Form 10-Q for the quarter ended March 31, 2026, which shows cash and cash equivalents of $3.4 million, a net loss of $1.553 million for the quarter, and a secured contingent payment obligation carried at fair value of $40.144 million. Shares outstanding were 147,767,649 as of May 1, 2026. The company discloses substantial doubt about its ability to continue as a going concern for one year absent licensing proceeds, conversions/extensions of convertible notes, or additional financing.
ParkerVision, Inc. reported another weak quarter as it continues to rely on patent litigation and licensing. The company generated no licensing revenue in Q1 2026 and posted a net loss of about $1.6 million, narrower than the $3.8 million loss a year earlier, mainly due to lower legal and professional fees and a smaller increase in contingent payment obligations.
Cash and cash equivalents were about $3.4 million at March 31, 2026, with working capital of roughly $1.7 million. Total assets were only $4.5 million against total liabilities of about $50.0 million, leaving shareholders’ deficit near $45.5 million. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern over the next year.
ParkerVision’s capital structure remains highly leveraged to future litigation outcomes. The fair value of its secured contingent payment obligation to litigation funder Brickell Key Investments was $40.1 million, with an underlying note carrying roughly $69.4 million of face value plus accrued interest. Unsecured contingent payment obligations totaled about $6.3 million. In March 2026, the company exchanged around $0.7 million of convertible notes and interest for approximately 3.3 million unregistered common shares, realizing a small loss on extinguishment.
ParkerVision, Inc. reported results for the three months ended March 31, 2026. Licensing revenue was $0 and net loss was $1.553 million, compared with a net loss of $3.799 million a year earlier, or $0.01 per share versus $0.03 per share.
Cash and cash equivalents were $3.423 million as of March 31, 2026, down from $4.360 million at year-end 2025. The balance sheet shows contingent payment obligations of $46.486 million and shareholders’ deficit of $45.524 million.
The company highlighted legal developments, including the Court of Appeals for the Federal Circuit granting an expedited schedule in its appeal in ParkerVision v. Qualcomm, with oral arguments set for June 1, 2026, and noted ongoing patent cases in Texas.
ParkerVision, Inc. files a prospectus supplement updating a resale registration that permits the resale of 9,387,500 shares of Common Stock. The registered shares consist of (i) 2,843,750 shares issued under purchase agreements, (ii) 6,343,750 shares issuable on conversion of convertible notes with a fixed conversion price of $0.16 per share, and (iii) 200,000 shares issuable upon exercise of options. The company states it will not receive proceeds from selling shareholders; however, it may receive up to $42,620 if the 200,000 Options are exercised for cash. The supplement also attaches a Form 8-K disclosing that the Compensation Committee extended the expiration dates of existing, fully vested nonqualified stock options for the CEO (2,660,000 options) and CFO (870,550 options) from August 7, 2026 to August 7, 2029, with no change to exercise price ($0.171) or share counts and an expected one-time non-cash share-based compensation charge of approximately $360,000.
ParkerVision, Inc. files a Prospectus Supplement registering 16,638,353 shares of Common Stock for resale by selling shareholders, consisting of shares issuable upon conversion of convertible promissory notes dated between May 10, 2022 and August 3, 2022 with a fixed conversion price of $0.13 per share. The supplement incorporates an attached Form 8-K dated April 22, 2026. The 8-K discloses that the Compensation Committee approved an extension of expiration dates for certain fully vested nonqualified stock options granted on August 7, 2019—2,660,000 options for CEO Jeffrey Parker and 870,550 options for CFO Cynthia French—moving the expiration from August 7, 2026 to August 7, 2029. The company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 related to that modification.
ParkerVision, Inc. is updating its resale prospectus to cover 1,578,946 shares of Common Stock available for resale by a selling stockholder, consisting of 1,052,631 shares and 526,315 shares issuable upon exercise of related warrants. The company will not receive proceeds from the resale; if the Warrants are exercised for cash, the company would receive up to $526,315. The supplement attaches a Form 8-K filed April 27, 2026 and also discloses that the Compensation Committee extended certain executive stock options' expiration dates to August 7, 2029, with an expected one-time non-cash share-based charge of approximately $360,000.
ParkerVision, Inc. files a Prospectus Supplement registering 13,342,953 shares of Common Stock for resale by selling stockholders under its shelf prospectus. The supplement states the company will receive no proceeds from resales; cash proceeds up to $2,833,756 are possible if outstanding warrants are exercised.
The filing also attaches a Form 8-K disclosing that the Compensation Committee extended expiration dates for previously issued, fully vested nonqualified stock options for CEO Jeffrey Parker (2,660,000 options) and CFO Cynthia French (870,550 options) from August 7, 2026 to August 7, 2029. The exercise price remains $0.171 per share. The company expects a one-time non-cash share-based compensation charge of approximately $360,000.
ParkerVision, Inc. files a Prospectus Supplement registering 5,871,584 shares of Common Stock for resale by selling stockholders. The supplement attaches a Form 8-K reporting that on April 22, 2026 the Compensation Committee extended the expiration dates of previously granted, fully vested nonqualified stock options held by CEO Jeffrey Parker (2,660,000 options) and CFO Cynthia French (870,550 options) from August 7, 2026 to August 7, 2029 with no change to exercise price ($0.171) or share counts. The company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 related to the modification. The resale proceeds will not be received by the company.
ParkerVision, Inc. registers 16,809,295 shares of Common Stock for resale under a prospectus supplement dated April 27, 2026.
The supplement states the 16,809,295 shares consist of convertible-note conversions, prior private placements, shares issued for services and payables, and warrants, and that the company will not receive proceeds from selling stockholders. The company may receive up to $3,900,000 if Aspire and Tailwinds warrants are exercised for cash; any proceeds are expected to be used for general working capital and corporate purposes.
Separately, the company disclosed a Compensation Committee action dated April 22, 2026 extending the expiration dates of outstanding options for the CEO (2,660,000 options) and CFO (870,550 options) from August 7, 2026 to August 7, 2029, which will result in an expected one-time non-cash share-based compensation charge of approximately $360,000.
ParkerVision, Inc. registers 18,014,164 shares of Common Stock for resale by selling stockholders under a prospectus supplement dated April 27, 2026.
The registration covers shares issuable upon conversion of convertible promissory notes across two tranches, shares issued for consulting services, and up to 1,800,000 shares issuable on a warrant with a $0.10 exercise price. The company will not receive proceeds from resales; if the Park Consulting Warrant is exercised for cash, the company would receive up to $180,000 to use for general working capital. The supplement attaches a Form 8-K reporting the Board Compensation Committee's approval to extend option expirations for two executives from August 7, 2026 to August 7, 2029, which will generate an estimated one-time, non-cash share-based compensation charge of approximately $360,000.